PMID- 10880046
OWN - NLM
STAT- MEDLINE
DCOM- 20000727
LR  - 20181113
IS  - 0021-9738 (Print)
IS  - 0021-9738 (Linking)
VI  - 106
IP  - 1
DP  - 2000 Jul
TI  - Antiviral treatment normalizes neurophysiological but not movement abnormalities 
      in simian immunodeficiency virus-infected monkeys.
PG  - 37-45
AB  - Simian immunodeficiency virus (SIV) infection of rhesus monkeys provides an 
      excellent model of the central nervous system (CNS) consequences of HIV 
      infection. To discern the relationship between viral load and abnormalities 
      induced in the CNS by the virus, we infected animals with SIV and later 
      instituted antiviral treatment to lower peripheral viral load. Measurement of 
      sensory-evoked potentials, assessing CNS neuronal circuitry, revealed delayed 
      latencies after infection that could be reversed by lowering viral load. 
      Cessation of treatment led to the reappearance of these abnormalities. In 
      contrast, the decline in general motor activity induced by SIV infection was 
      unaffected by antiviral treatment. An acute increase in the level of the 
      chemokine monocyte chemoattractant protein-1 (MCP-1) was found in the 
      cerebrospinal fluid (CSF) relative to plasma in the infected animals at the peak 
      of acute viremia, likely contributing to an early influx of immune cells into the 
      CNS. Examination of the brains of the infected animals after return of the 
      electrophysiological abnormalities revealed diverse viral and inflammatory 
      findings. Although some of the physiological abnormalities resulting from SIV 
      infection can be at least temporarily reversed by lowering viral load, the 
      viral-host interactions initiated by infection may result in long-lasting changes 
      in CNS-mediated functions.
FAU - Fox, H S
AU  - Fox HS
AD  - Department of Neuropharmacology, The Scripps Research Institute, La Jolla, 
      California, USA. hsfox@scripps.edu
FAU - Weed, M R
AU  - Weed MR
FAU - Huitron-Resendiz, S
AU  - Huitron-Resendiz S
FAU - Baig, J
AU  - Baig J
FAU - Horn, T F
AU  - Horn TF
FAU - Dailey, P J
AU  - Dailey PJ
FAU - Bischofberger, N
AU  - Bischofberger N
FAU - Henriksen, S J
AU  - Henriksen SJ
LA  - eng
GR  - R01 MH059468/MH/NIMH NIH HHS/United States
GR  - MH-55836/MH/NIMH NIH HHS/United States
GR  - MH-59468/MH/NIMH NIH HHS/United States
GR  - MH-61224/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
RN  - 0 (Antiviral Agents)
SB  - IM
CIN - J Clin Invest. 2000 Jul;106(1):11-3. PMID: 10880043
MH  - Animals
MH  - Antiviral Agents/*therapeutic use
MH  - Blood-Brain Barrier
MH  - Brain/drug effects/*physiopathology/virology
MH  - Evoked Potentials, Auditory, Brain Stem/drug effects
MH  - Macaca mulatta
MH  - Motor Activity/drug effects
MH  - Movement Disorders/*drug therapy
MH  - Simian Acquired Immunodeficiency Syndrome/*drug therapy/physiopathology/virology
MH  - Simian Immunodeficiency Virus/isolation & purification
PMC - PMC314358
EDAT- 2000/07/06 00:00
MHDA- 2000/07/06 00:01
PMCR- 2000/07/01
CRDT- 2000/07/06 00:00
PHST- 2000/07/06 00:00 [pubmed]
PHST- 2000/07/06 00:01 [medline]
PHST- 2000/07/06 00:00 [entrez]
PHST- 2000/07/01 00:00 [pmc-release]
AID - 09102 [pii]
AID - 10.1172/JCI9102 [doi]
PST - ppublish
SO  - J Clin Invest. 2000 Jul;106(1):37-45. doi: 10.1172/JCI9102.